HR 1956 · 110th Congress 2007–2009, ended

Patient Protection and Innovative Biologic Medicines Act of 2007

Latest action · Apr 20, 2007 Referred to the Subcommittee on Health.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedApr 19, 2007
  2. Passed HouseNot reached
  3. Passed SenateNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Patient Protection and Innovative Biologic Medicines Act of 2007 - Amends the Public Health Service Act to allow any person to submit an application for approval of a biologics license for a biological product that is claimed to be similar to a qualified biological product (reference product) after 12 years have elapsed since the reference product was approved or licensed.

Allows the Secretary of Health and Human Services to approve such a similar biological product: (1) only if the applicant demonstrates that the product conforms to the applicable final product-class specific guidance and the Secretary concludes the product is safe, pure, and potent; (2) only for indications for which the reference product is approved; and (3) to be effective only after at least 14 years have elapsed since the reference product was approved or licensed.

Prohibits the Secretary from designating a similar biological product as therapeutically equivalent to the reference product.

Prohibits the Secretary from approving a product that is claimed to be similar to or the same as a reference product under any other provision of law.

Authorizes any person to request issuance of product-class specific guidance applicable to a qualified biological product and its class.

Requires the Secretary to establish a Similar Biological Products Advisory Committee.

Sets forth provisions governing the naming of biotechnology-derived therapeutic protein and other biological products. Amends the Federal Food, Drug, and Cosmetic Act to deem a biotechnology-derived therapeutic protein to be misbranded if its labeling fails to meet the requirements of this Act.

Cosponsors 25

Members who signed on, in the order they did. Signatures ran from Apr 19, 2007 to Sep 23, 2008; 2 are original cosponsors, there from the day it was introduced.

SeatCosponsorSigned on
D-TXGene GreenOriginalApr 19, 2007
D-WITammy BaldwinOriginalApr 19, 2007
D-NYEdolphus TownsMay 1, 2007
D-NCG. K. ButterfieldMay 9, 2007
D-WAAdam SmithMay 17, 2007
D-ALArtur DavisMay 17, 2007
D-WIRon KindMay 17, 2007
D-CAEllen O. TauscherMay 21, 2007
D-NYJoseph CrowleyMay 21, 2007
D-NYGregory W. MeeksMay 24, 2007
D-LACharlie MelanconJun 25, 2007
D-NYTimothy H. BishopJun 28, 2007
D-VAJames P. MoranJul 17, 2007
D-ORDarlene HooleyJul 31, 2007
D-INBaron P. HillSep 25, 2007
D-CALaura RichardsonJan 29, 2008
D-INAndré CarsonApr 29, 2008
D-PAPatrick J. MurphyMay 15, 2008
D-PAJoe SestakJun 3, 2008
R-TXRon PaulJun 3, 2008
D-WISteve KagenJul 31, 2008
D-CAJoe BacaSep 9, 2008
D-PAChristopher P. CarneySep 23, 2008
D-GAJohn BarrowSep 23, 2008
D-TXRuben HinojosaSep 23, 2008

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseEnergy and Commerce Committee
Referred Apr 19, 2007
Health Subcommittee
Referred Apr 20, 2007

Actions 3

Everything that happened, newest first.

  1. Apr 20, 2007Referred to the Subcommittee on Health.
  2. Apr 19, 2007Introduced in House
  3. Apr 19, 2007Referred to the House Committee on Energy and Commerce.

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Printed hearings 2

Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.

NumberHearingCommitteeHeld
Serial No. 110-187BUSINESS ACTIVITY TAX SIMPLIFICATION ACT OF 2008237 pagesJudiciary CommitteeJun 24, 2008
Serial No. 110-40ASSESSING THE IMPACT OF A SAFE AND EQUITABLE BIOSIMILAR POLICY IN THE UNITED STATES190 pagesEnergy and Commerce CommitteeMay 2, 2007

CRS reports 1

Congressional Research Service work that CRS links to this bill or the law it became, newest first.

Cite it 1

Products on other subjects that cite it, usually among other measures.

ProductTitleKindPublished
RL34045FDA Regulation of Follow-On Biologics ArchivedReportApr 26, 2010

Titles 2

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To amend the Public Health Service Act to provide for the approval of similar biological products, and for other purposes.
Short Titles as Introduced
Patient Protection and Innovative Biologic Medicines Act of 2007

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Apr 19, 2007Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.